



BEST AVAILABLE COPY

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: ABLE-0021
Inventors: Sacombas et al.
Serial No.: 10/088,780
Filing Date: July 22, 2002
Examiner: Kelly, Robert M.
Group Art Unit: 1632
Title: Monoclonal Antibody 3F1H10 Neutralising
VHSV (Viral Haemorrhagic Septicaemia
Virus)

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Declaration by Niels Lorenzen, Ph.D.

I, Niels Lorenzen hereby declare:

1. I am a coinventor of the above-referenced patent application.

2. In addition to the experiments set forth in the above-referenced patent application in fish, we have also ^{prepared (x)} inserted a gene ^{and tested it (x)} construct encoding a single-chain antibody to a toxin in mice. The insert gene construct was very similar to that used in the experiments described in the above-referenced patent application with the antibody gene being inserted downstream of a CMV promoter. The plasmid was delivered to the mice routinely via intramuscular injection followed by electroporation such as described at page 7,

x changes made by Niels Lorenzen

Niels Lorenzen


BEST AVAILABLE COPY

Attorney Docket No.: ABLE-0021
Inventors: Sacombas et al.
Serial No.: Not yet assigned
Filing Date: Herewith
Page 2

lines 20 through 25 of the above-referenced patent application. A delay or inhibition of the toxic effect of the toxin was observed when the mice were later exposed to the toxin.

I further hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information or belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or by imprisonment, or both under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing there upon, or any patent to which this verified statement is directed.

Date: September 3, 2004


Niels Lorenzen